Lung cancer
Conditions
Interventions
Group C :Immunotherapy Combined with Chemotherapy and anti-vascular therapy:None
Group B (Immunotherapy Combined with Anti-Angiogenic Therapy): ICI + Anti-Angiogenic Drugs (Such as Bevacizumab)
:None
Group D (Control group: Non-immunotherapy group): Received any treatment plan that does not include ICI, such as chemotherapy alone, anti-vascular therapy alone, or targeted drugs combined with chemot
Group A (Immunotherapy Combined with Chemotherapy): ICI + Platinum-Based Doublet Chemotherapy
Group D (control group: non-ICI immunotherapy group): received any treatment regimen not including ICI, such as chemotherapy alone, anti-angiogenic therapy alone, or targeted therapy combined with che
Sponsors
Yuebei People’s Hospital
Eligibility
Sex/Gender
All
Age
22 Years to 78 Years
Inclusion criteria
Inclusion criteria: 1. EGFR-mutated non-small cell lung cancer (NSCLC) 2. Progression following treatment with first- to third-generation tyrosine kinase inhibitors (TKI) (RECIST 1.1 criteria) 3. Receiving second-line therapy (immune checkpoint inhibitors/chemotherapy/anti-angiogenic therapy combination).
Exclusion criteria
Exclusion criteria: 1. Concurrent mutations in other driver genes (ALK/ROS1) 2. Presence of contraindications to immune checkpoint inhibitors (ICIs).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Real-world progression-free survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Real-world overall survival;Objective response rate; | — |
Countries
China
Contacts
Public ContactHuiyong Chen
Yuebei People’s Hospital
Outcome results
None listed